Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Saturday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ ADXS opened at $0.03 on Friday. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $1.49. The stock has a 50 day moving average of $0.04 and a 200-day moving average of $0.07. The company has a market cap of $1.15 million, a PE ratio of 0.00 and a beta of 1.70.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.